Medical/Pharmaceuticals
Maypharm Announces New Product METOX on Times Square in New York
SEOUL, South Korea and NEW YORK, Jan. 26, 2021 /PRNewswire/ -- Maypharm
announces new botulinum toxin, METOX onJanuary 26, 2021. METOX is an effective
solution for smoothing any kind of wrinkles from moderate to severe, caused by
daily active facial movements.
2021-01-26 17:00
1906
I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer
SHANGHAI, China and PLANEGG/MUNICH, Germany, Jan. 25, 2021 /PRNewswire/ -- I-Mab (Nasdaq: IMAB), and MorphoSys (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) today announced that the first patient has been dosed in a phase 1 dose escalation study to evaluate the safety, tolerabili...
2021-01-26 05:05
3699
BioNTech and Fosun Pharma Receive Authorization for Emergency Use in Hong Kong for COVID-19 Vaccine
MAINZ, Germany and SHANGHAI, China, 25 Jan. 2021 /PRNewswire/ -- BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") andShanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "Group"; Stock Code: 600196.SH, 02196.HK) today announced that according to the Food and Health Bureau of ...
2021-01-26 01:18
6375
VolitionRx Limited Opens its New Manufacturing Facility in Belgium
AUSTIN, Texas, Jan. 25, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the opening of "Silver One", its 10,000 square foot dedicated manufacturing facility located on the same science park as its Research and Development laboratory in Isnes,Belgium. Vol...
2021-01-25 21:45
8520
China Biologic Announces Extraordinary General Meeting of Shareholders
BEIJING, Jan. 25, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that it has called an extraordinary general meeting of shareholders (the "EGM...
2021-01-25 21:44
9704
BioVaxys Announces Initiation Of Cancer Vaccine EU Clinical Program, Completion Of BVX-0320 Preclinical Program
VANCOUVER, BC, Jan. 25, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys" or "Company") is pleased to provide a corporate update on recent advancements of its vaccine platforms, and viral diagnostic and corporate objectives for 2021. BioVaxys is ple...
2021-01-25 21:00
3738
European Commission Approves BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
- BAVENCIO maintenance treatment significantly extended median overall survival versus standard of care in the Phase III JAVELIN Bladder 100 study - First and only immunotherapy to demonstrate a significant overall survival benefit in the first-line setting in a Phase III trial - BAVENCIO firs...
2021-01-25 15:00
4679
Boehringer Ingelheim named Top Employer in Malaysia, across Southeast Asia, and South Korea for 2021
KUALA LUMPUR, Malaysia, Jan. 25, 2021 /PRNewswire/ -- Boehringer Ingelheim has been recognized as a Top Employer for 2021 inMalaysia and six other countries acrossAsia - Indonesia, Philippines, Singapore, South Korea, Thailand and Vietnam - by Top Employers Institute, the global authority on exce...
2021-01-25 10:00
2596
Boehringer Ingelheim named Top Employer in Vietnam, across Southeast Asia, and South Korea for 2021
HO CHI MINH CITY, Vietnam, Jan. 25, 2021 /PRNewswire/ -- Boehringer Ingelheim has been recognized as a Top Employer for 2021 inVietnam and six other countries acrossAsia - Indonesia, Malaysia, Philippines, Singapore, South Korea andThailand - by Top Employers Institute, the global authority on ex...
2021-01-25 10:00
2773
Boehringer Ingelheim named Top Employer in Philippines, across Southeast Asia, and South Korea for 2021
MAKATI CITY, Philippines, Jan. 25, 2021 /PRNewswire/ -- Boehringer Ingelheim has been recognized as a Top Employer for 2021 inPhilippines and six other countries acrossAsia - Indonesia, Malaysia, Singapore, South Korea, Thailand and Vietnam - by Top Employers Institute, the global authority on ex...
2021-01-25 10:00
2315
Boehringer Ingelheim named Top Employer in Singapore, across Southeast Asia, and South Korea for 2021
SINGAPORE, Jan. 25, 2021 /PRNewswire/ -- Boehringer Ingelheim has been recognized as a Top Employer for 2021 inSingapore and six other countries across Asia - Indonesia, Malaysia, Philippines, South Korea, Thailand and Vietnam - by Top Employers Institute, the global authority on excellence in peo...
2021-01-25 10:00
2805
Boehringer Ingelheim named Top Employer in Thailand, across Southeast Asia, and South Korea for 2021
BANGKOK, Jan. 25, 2021 /PRNewswire/ -- Boehringer Ingelheim has been recognized as a Top Employer for 2021 inThailand and six other countries across Asia - Indonesia, Malaysia, Philippines, Singapore, South Korea and Vietnam - by Top Employers Institute, the global authority on excellence in peop...
2021-01-25 10:00
2326
Boehringer Ingelheim named Top Employer in Indonesia, across Southeast Asia, and South Korea for 2021
JAKARTA, Indonesia, Jan. 25, 2021 /PRNewswire/ -- Boehringer Ingelheim has been recognized as a Top Employer for 2021 inIndonesia and six other countries across Asia - Malaysia, Philippines, Singapore, South Korea, Thailand and Vietnam - by Top Employers Institute, the global authority on excellen...
2021-01-25 10:00
2577
Antengene Announces Approval of IND Application in China for ATG-010 (Selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study
SHANGHAI and HONG KONG, Jan. 25, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncol...
2021-01-25 08:20
3258
Nanoform's Clinical Study Indicates Positive Interim Results
HELSINKI, Jan. 22, 2021 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medicine enabling company, today announced positive interim results from its clinical study. The faster absorption data implies that small particles can indeed be powerful. Nanoform has received...
2021-01-22 15:43
1780
Elekta divests its stake in ViewRay
STOCKHOLM, Jan. 22, 2021 /PRNewswire/ -- Elekta AB (EKTA-B.ST) announced today that it has sold its 7.3 percent of the outstanding common stock (11,501,597 shares) in ViewRay, Inc. (Nasdaq:VRAY). Elekta has no remaining shares in ViewRay after the transaction. The shares in ViewRay were purchase...
2021-01-22 14:51
5320
GS1 HK and Zenecom join hands to help local merchants seize trillions O2O opportunities in Mainland medical, healthcare and beauty markets
HONG KONG, Jan. 22, 2021 /PRNewswire/ -- GS1 Hong Kong (GS1 HK) and Zenecom International Group Co. Ltd (Zenecom) formally signed a strategic cooperation agreement to launch "HK Trusted Market + WJH" initiative. Capitalising on the cross-border "Big Health" e-commerce platform WJH, the programme ...
2021-01-22 14:25
2648
Nippon Express (China) Inks MOU on Logistics Business Partnership with Jointown Pharmaceutical Group Logistics
TOKYO, Jan. 22, 2021 /PRNewswire/ -- Nippon Express (China) Co., Ltd. (hereinafter "NE China"), a subsidiary of Nippon Express Co., Ltd. of Tokyo, signed a memorandum of understanding (MOU) onDecember 18, 2020, over business partnership with Jointown Pharmaceutical Group Logistics Co., Ltd. (here...
2021-01-22 14:00
3941
DWHP Announces Extension of The Expiration Time of Its Tender Offer
PARK CITY, Utah, Jan. 22, 2021 /PRNewswire/ -- DW Healthcare Partners V, L.P. (" DWHP"), announced today that it is extending the expiration time of its previously announced cash tender offer (the "Tender Offer") in the Offer to Purchase datedDecember 21, 2020 ("Offer to Purchase") for all of the ...
2021-01-22 12:34
9851
Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for Patients with Severe COVID-19
TAIPEI and SAN DIEGO, Jan. 21, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that the first patient has enrolled into an investi...
2021-01-22 12:00
2172
Week's Top Stories
Most Reposted
Radisson Hotel Group accelerates growth in Indonesia with ANTA Hotel Bali Canggu, a member of Radisson Individuals
[Picked up by 313 media titles]
2025-12-10 10:00
HKSTP Makes Strategic Investment in Singapore Technology Company Vizzio; Forges Innovation Pact to Power Next-Generation AI and Smart City
[Picked up by 306 media titles]
2025-12-09 13:31
ARKANCE to Launch BIMLOGIQ - A New AI-Powered Extension to Its AEC Tech Stack Offering
[Picked up by 293 media titles]
2025-12-11 09:07
BeLive Studios, NewUnivers and ChopChop Systems Sign Memorandum of Understanding at ATF 2025
[Picked up by 288 media titles]
2025-12-08 11:00
Tiiny AI Reveals World's Smallest Personal AI Supercomputer, Verified by Guinness World Records
[Picked up by 286 media titles]
2025-12-10 16:00